Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

In PROPEL 3, 52 weeks of oral infigratinib treatment showed favorable trends versus placebo across clinically meaningful exploratory endpoints, including sleep apnea and otitis media events. The limited disclosure provides a positive clinical signal, but no quantitative efficacy, safety, or regulatory data were reported.